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Benefit sharing is the process or act of sharing in the 
benefits that derive from research in a manner that 
is fair and equitable.[1] When considering benefits 
generated from genetic research, it is unclear how, 
with whom and by which mechanisms these benefits should be 
shared, as this area of discussion is somewhat unexplored.[2] In addi­
tion, the necessity for benefit sharing may be resisted specifically 
when international institutions from the developed world fund re­
search projects within a developing world country. However, the idea 
of benefit sharing must be balanced with public interests and popu­
lation health.[2,3] The philosophical principle behind the concept 
of benefit sharing is simple and may be argued as a matter of 
justice.[4] Those who contribute to scientific research ought to share 
in its benefits.[4] This is particularly relevant in terms of health research, 
when the exploitation of South Africa (SA) and the developing world 
by developed world countries is considered.[2,5] This inequity still 
exists in certain spheres and needs to be corrected in order to restore 
equilibrium.[2] A benefit should be received by research participants 
and/or the institution which provides the samples for the utilisation 
of their genetic resources and/or resources.[2] With the use of two case 
studies and relevant national and international laws and guidelines, 
this paper will debate the requirement of benefit sharing when 
research is undertaken; discuss its meaning in the context of genetic 
research; and outline some SA and international perspectives on the 
sharing of benefits. While this paper emphasises benefit sharing in 
the context of genetic research, the principles apply to all human 
participant research.
The importance of benefit sharing when 
research is undertaken and its meaning in 
the context of genetic research
Reliance on the use of human biobanks for research purposes has 
increased. In addition, the capacity, size and number of biobanks, 
has intensified.[2] Human biobanks are capable of storing a vast 
array of genetic data including stem cells for indefinite periods, for 
uses that may not be established at the time the initial protocol 
is approved (secondary uses). Ethico­legal complications that 
storage of data for indefinite periods gives rise to, include (but 
are not limited to): confidentiality; privacy; ownership; intellectual 
property; informed consent for secondary uses; and benefit 
sharing.[2] Justifiably, the complexities that result with the advances 
challenge local and international ethico­legal frameworks. Of 
considerable importance and debate is the notion of benefit 
sharing. 
There is argument that participation in scientific research should 
always be altruistic in nature. This is how access to human genetic 
resources has been governed historically in prosperous nations.[6] 
However, exporting this notion into developing countries could 
lead to the emergence of serious concerns around exploitation. A 
discussion of two relevant cases below, that involve benefit sharing 
mechanisms, describe how positive outcomes could be arrived 
at while engaging in benefit sharing within developing world 
communities. 
The Majengo case study
The Majengo sex workers case involved follow­up studies on 
850 female sex workers in Kenya. It was thought that they could 
contribute to the development of a vaccine against HIV. This was 
part of an ongoing collaborative project by researchers from the 
universities of Nairobi and Manitoba.[6,7]  The women were extremely 
socio­economically disadvantaged and unable to access quality 
healthcare in any other way than through their involvement in the 
clinic which was set up by the research team.[8]  The women provided 
individual informed consent to participate in the ongoing study 
which utilised their blood, cervical, vaginal and saliva samples.[7,8] 
The Kenyan regulatory environment includes access to non­human 
genetic resources and subsequent benefit sharing thereof. However, 
no regulation or policy existed in respect of human genetic resources. 
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In 2005, national guidelines for research and development of HIV/
AIDS vaccines[7,9] were developed in specific response to the Majengo 
case. These guidelines provide a framework for addressing issues of 
financial compensation for research participants through Material 
Transfer Agreements (MTAs) and Research and Development Agree­
ments.[7,9] The guideline’s MTA template provides for the ‘fair and 
equitable sharing of benefits’ derived from the use of biological 
materials.[10]  An argument has been made that benefit sharing 
agreements could effectively be incorporated into the cooperative 
research and development agreements. These agreements will then 
be binding and enforceable in domestic law.[7,8] The Kenyan guidelines 
further require science and ethics committees in the country to verify 
the ethical integrity of HIV/AIDS vaccine trial protocols in accordance 
with internationally accepted ethical guidelines, for example, the 
ethical considerations in HIV preventative vaccine research of the 
joint United Nations programme on HIV/AIDS (UNAIDS).[7,9] Guidance 
Point 10 of the aforementioned document states that: ‘The research 
protocol should outline the benefits that persons participating in 
HIV preventative vaccine trials should experience as a result of their 
participation. Care should be taken so that these are not presented 
in a way that unduly influences freedom of choice in participation.’[11] 
While this guidance document is not legally enforceable, it does list 
what should be considered as minimum benefits for participants in 
HIV preventative vaccine trials. 
The main benefit received by the Majengo participants in the 
study was healthcare.[7] Prior to the research team establishing a 
clinic in the slums of Majengo, the participants had no option but to 
utilise a treatment centre in Nairobi, where services were poor and 
where healthcare providers discriminated against sex workers.[7,8,12] 
The sex workers now have non­discriminatory access to healthcare 
within walking distance. Apart from the direct benefits in terms of 
healthcare, the clinic also offers a ‘safe haven’[7,8] which enables the 
women to form new relationships, social networks and develop a 
sense of solidarity, creating a community environment. Additionally, 
research publications have brought the participants international 
exposure which could assist in safeguarding the women’s rights to any 
benefits that may accrue from ongoing research activities. This case 
outlines a situation where, as a direct result of the research process, 
participants benefited both physically and socially by gaining access 
to much needed healthcare. The research also displayed that, with 
the right motivation, a disadvantaged and poor population could 
manage the demands of antiretroviral treatment and achieve the 
same adherence levels as the general population. This unforeseen 
outcome is of great significance and benefit to all those affected by 
HIV/AIDS, independent from the search for a successful preventative 
vaccine.[7,8] 
The San Hoodia case
The next scenario does not involve human genetic material; however, 
it is an example of how one of the first benefit sharing agreements 
was negotiated in SA in the absence of an enabling domestic legal 
environment. The San people (among the oldest communities in 
southern Africa) historically acquired traditional knowledge on the use 
of Hoodia gordonii, a moist plant found in the Kalahari desert, which 
the San have customarily consumed to limit hunger on their lengthy, 
tiring journeys.[13] The San people were at first unaware that the South 
African Council for Scientific and Industrial Research (CSIR), an arm of 
the SA government, were patenting an appetite suppressant which 
was produced from the Hoodia plant.[13] No credible clinical trials 
have, to date, documented its safety or efficacy. The CSIR also had 
plans to commercialise a Hoodia pharmaceutical product without 
the San people providing their consent, and there was no discussion 
surrounding the sharing of benefits derived from the subsequent 
commercialisation.[13] The CSIR and Phytopharm, a pharmaceutical 
com pany with a plant extract division, negotiated an exclusive license 
that transferred rights for research and commercial use of the patent for 
the development of Hoodia products. Phytopharm then granted licen ses 
to Pfizer and the food multinational, Unilever.[13] With the involve ment 
of NGOs, in 2003 the San people and the CSIR negotiated one of the 
first benefit sharing agreements.[13] This provided the San with a share 
of the royalties derived from the sale of the products containing 
Hoodia.[13] The benefit sharing agreement received criticism;[13] 
however, although far from perfect, it is an example for potential 
future benefit sharing agreements which allow for communities 
to receive recognition for their traditional knowledge and share in 
the commercialisation of products based on their knowledge.[13] 
South African law and guidelines with 
regard to the sharing of benefits 
The Biodiversity Act 10 of 2004
In SA, the Biodiversity Act 10 of 2004[14] is the only legal document 
that sets out what a ‘benefit’ may constitute for bioprospecting or any 
other kind of research involving indigenous biological resources. The 
Act specifically excludes human material from its application, but it 
does provide for (among others): the sustainable use of indigenous 
biological resources; and the fair and equitable sharing of benefits 
arising from bioprospecting or involving indigenous biological res­
ources.[14] Currently, section 1 of the Act defines a benefit to include: 
‘both monetary and non­monetary returns’.[14] Therefore, local 
capacity building would form a benefit as provided for under the Act. 
Section 81(1)(b) of the Act also: ‘obligates applicants to apply for a 
permit before any export of the resource is undertaken for research 
purposes’.[14] In addition, section 82(1)(b) of the Act: ‘protects the 
interests of any organ of state or community providing or giving 
access to the indigenous biological resources’. The involvement of 
the indigenous community is measured before any permit referred 
to above is issued.[14] With regard to the protection of an indigenous 
community, the issuing authority will consider the traditional 
uses of the indigenous biological resources or the knowledge of, 
or discoveries about the indigenous biological resources before 
authorising a permit for use of the resources.[14] Section 82(2)(b) of 
the Act makes it mandatory for the applicant and stakeholder (i.e. 
a person, organ of state, community or indigenous community) to 
enter into an MTA which regulates the provision of or access to the 
resources and a benefit sharing agreement that provides for sharing 
by the stakeholder in any future benefits that may be derived from the 
relevant bioprospecting.[15] It is important to note that a permit will 
not be granted if the preceding two agreements are not entered into 
by the parties. Section 83 of the Act sets out that the benefit sharing 
agreement must specify: ‘the type of indigenous biological resources 
to which the relevant bioprospecting relates; the area or source from 
which the indigenous biological resources are to be collected or 
obtained; the quantity of resources to be collected or obtained; any 
traditional uses of the resources by an indigenous community; and 
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the present potential uses of the resources’.[16] The benefit sharing 
agreement must also name the parties to the agreement; set out the 
manner and extent to which the resources are to be utilised; set out 
the manner and extent to which the stakeholder will share in any 
benefits that may arise; provide for regular review of the agreement; 
and comply with any other matters that may be prescribed.[17] Section 
83(5) of the Act stipulates that the agreement or any amendment 
thereto will have to be submitted to the Minister for approval and will 
not take effect unless approved by the Minister. Section 85 of the Act 
provides for any monies arising from the benefit sharing agreement 
and MTA and directs that such monies are kept in a bioprospecting 
trust fund and considered to be trust money managed by the director 
general who will be accountable for these funds. 
As stated above, the Biodiversity Act is the only SA piece of legislation 
that regulates benefit sharing agreements in terms of providing a 
definition and outlining what the agreement should contain. Although 
human material is excluded from the Act, it is a relevant starting point 
to develop a benefit sharing mechanism of a similar nature, relevant to 
research involving human material, as has been done recently in the 
University of the Witwatersrand’s MTA template.
University of the Witwatersrand’s Material 
Transfer Agreement template
During 2014, the University of the Witwatersrand approved an 
MTA template[1] for human biological materials to be used by its 
researchers. The definitions section of the template defines benefit 
sharing as: ‘a process or act of sharing in the benefits that derive 
from the research in a manner that is fair and equitable’.[1] The 
template also defines benefits to include among others: ‘the sharing 
of information, use of research results, royalties, acknowledgement 
of the provider as the source of the materials, publication rights, 
transfer of technology or materials, and capacity building’.[1] In 
an attempt to foster equitable benefit sharing mechanisms, the 
template provides that the sharing of benefits should be discussed 
between the parties before any materials are transferred for 
research purposes. 
Ethics in health research: Principles, structures 
and processes 
This ethical guideline provides guidance in respect of all forms of 
research involving animals, human participants, human biological 
materials and data collected from living or deceased persons, 
including human embryos, fetuses, fetal tissue, reproductive materials 
and stem cells.[18]  South African research ethics committees are 
encouraged to adopt these principles in assessing all health research 
projects.[18] The guideline provides that a risk­benefit analysis should 
precede carrying out the research and that the likelihood of benefits 
should outweigh the anticipated risk of harm to participants. The 
guideline further indicates that there should be a fair balance of risks 
and benefits among all role­players involved in research, including 
participants, participating communities and the broader society, in 
order to express the principle of equality in the research context. In 
addition, there should be a reasonable likelihood that the population 
from which participants are drawn, will benefit from the research 
results, if not immediately, then in the future.[18]
It may be argued that ethical guidelines have no legal status. 
However, it is important to note that in terms of current legal 
literature, ethical guidelines are considered as customary 
international law.[19] In order to qualify as customary international 
law, an ethics guideline must be supported by the consistency and 
generality of being widely accepted as practice.[19,20] Nevertheless, 
there is still a large gap between legislative documents with legal 
status and ethical guidelines.[19,20] Furthermore, it is difficult to 
compel objectors to the ethical guidelines to comply, which raises 
concerns surrounding the alleged binding nature of customary 
international law.[19] Section 39(1)(b) of the Constitution of South 
Africa instructs that when the Bill of Rights is interpreted, a court, 
tribunal or forum must consider international law.[21] However, 
without a legal requirement for the incorporation of benefit sharing 
agreements into the research process in SA, it is left up to ethics 
committees to regulate these arrangements on a case­by­case 
basis. In the absence of clear domestic legislation regarding benefit 
sharing in the context of human genetic research, a brief description 
of certain international perspectives relevant to research on human 
material will follow.
International perspectives on benefit 
sharing
The Nagoya protocol on access to genetic 
resources and the fair and equitable sharing of 
benefits arising from their utilisation
The Nagoya protocol on access to genetic resources and the fair 
and equitable sharing of benefits arising from their utilisation 
(ABS)[22] is a supplementary agreement to the Convention on 
Biological Diversity (CBD).[23] South Africa is a signatory to the 
protocol which provides for the effective implementation of the 
fair and equitable sharing of benefits arising out of the utilisation 
of genetic resources.[23] The Protocol was adopted on 29 October 
2010 in Nagoya, Japan. Of particular relevance is the reference 
to human genetic resources in the introduction. Similarly, it is 
important that: ‘access to affordable treatments by those in need 
especially in developing countries’ is included in Article 8 of the 
Protocol, among the special considerations that must be observed 
when regulating access to genetic resources.[22,23]
The Protocol creates incentives to safeguard and sustainably 
use genetic resources, therefore enhancing the contribution 
of biodiversity to development and human well­being.[22,23] 
Among the parties who are required to provide their informed 
consent and agree to mutual terms are indigenous and local 
communities that hold genetic resources and/or associated 
traditional knowledge.[23] With regard to benefit sharing, each 
party is obligated to take administrative, legislative or policy 
measures to ensure that benefits are shared fairly and equitably 
with the party who provides the resources.[24] Capacity building 
is also emphasised in the Protocol. Parties must participate in 
capacity development, capacity building, and strengthening of 
human resources and institutional capacities.[24] 
Under the Protocol, communities who hold genetic resources and 
related traditional knowledge are afforded extensive consideration 
and protection: 
• Prior informed consent must be provided by these communities for 
utilisation and access to their resources. 
• Benefits must be shared in a fair and equal manner with the 
communities whose genetic resources or traditional knowledge 
were utilised. 
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• Parties shall establish mechanisms to notify users of traditional 
knowledge about their obligations. 
• Parties shall organise community meetings, establish a help desk 
for communities, and involve communities in the implementation 
of the Protocol, to increase awareness of genetic resources and 
traditional knowledge held by communities.
• The Protocol further calls for capacities of communities to be 
improved, which will enable their effective participation in 
implementing the objectives of the Protocol.[22­24]
The Declaration on the Human Genome and 
Human Rights
The Declaration on the Human Genome and Human Rights[25] was 
adopted unanimously and by acclamation at UNESCO’s 29th general 
conference on 11 November 1997. The following year, the United 
Nations General Assembly endorsed the Declaration. Article 12(a) 
of the 1997 Declaration embraces the theory of sharing benefits on 
the basis of common property and distributive justice. It states that: 
‘Benefits from advances in biology, genetics and medicine concerning 
the human genome, shall be made available to all, with due regard 
for the dignity and human rights of each individual’. This implies 
that benefits concerning the human genome may be considered 
common property and therefore be made available to all.[19,25] Article 
19(a) iii indicates that: ‘when international co­operation occurs, 
developing countries should benefit from the achievements 
of scientific and technological research in order for their use in 
favour of economic and social progress to be for the benefit of all’. 
Two other international guideline documents, while not specific 
to genetic research, are also worthy of a brief discussion in this 
section and follow below.
The Council for International Organisations and 
Medical Sciences international ethical guidelines 
for biomedical research involving human subjects 
The goals of the Council for International Organisations and Medical 
Sciences (CIOMS) international ethical guidelines for biomedical 
research involving human subjects[26] are to facilitate and promote 
international activities in the field of biomedical sciences, in colla­
boration with the United Nations and the World Health Organization 
(WHO).[26,27] The CIOMS guidelines (developed in conjunction with the 
WHO) were published in 1993, and updated in 2002. The guide lines 
provide broad support, with regard to benefit sharing, and stipulate that 
a research project should leave low resource countries or communities 
better off than previously or, at least, not worse off.[26] The guidelines 
further stipulate that the project should be responsive to health needs 
and priorities in that any product developed is made reasonably 
available, and as far as possible leave the population in a better position 
to obtain effective healthcare and protect its own health.[26] 
The CIOMS guidelines that deal directly with benefit sharing 
are: guideline 10, which focuses on post­study access to beneficial 
interventions and responsiveness to health needs; and guideline 
21 which deals with the provision of services that are necessary for 
making a beneficial intervention and/or product available.[26]
Guideline 10 relates to research in populations and communities 
with limited resources. Before undertaking research in a population or 
community with limited resources, the sponsor and the investigator 
must make every effort to ensure that the research is responsive to 
the health needs and the priorities of the population or community 
in which it is to be carried out.[26] Furthermore, every effort must 
be made to ensure that any intervention or product developed, or 
knowledge generated, will be made reasonably available for the 
benefit of that population or community.[26] However, the issue of 
‘reasonable availability’ is complex and de ter mined on a case­by­
case basis.[26] The guidelines provide that in general, if there is good 
reason to believe that a product developed or knowledge generated 
by research is unlikely to be reasonably available to, or applied to the 
benefit of, the population of a proposed host country or community 
after the conclusion of the research, it is unethical to conduct the 
research in that country or community.[26] 
The Declaration of Helsinki 
The Declaration of Helsinki[28] was first adopted at the 1964 World 
Medical Association General Assembly in Helsinki. Its purpose is 
to provide ethical principles for medical research involving human 
subjects, including research on identifiable human material and 
data.[28]  Section 19 of the Declaration explains that certain groups or 
individuals may be considered to be vulnerable and should receive 
considered protection.[28] Section 20 states that medical research 
with a vulnerable group is only justified if the research is responsive 
to the health needs or priorities of the group.[28] Additionally, the 
group should stand to benefit from the knowledge, practices or 
interventions that result from the research.[28]
Discussion and conclusion
From the above analysis, it is clear that the international guidelines 
echo a similar message with regard to benefit sharing. In addition, it 
is apparent that benefit sharing in respect of human material does 
not imply a monetary transaction only. Any form of advantage, 
assistance or upliftment to the participant, community and/or 
providing institution could constitute a benefit and enhance the 
trust relationship between research participants and institutions, 
which in turn will foster progress in terms of genetic research. 
The international guidelines emphasise the importance of the 
concept of benefit sharing specifically with regard to developing 
world countries. With recent developments in the biotechnology 
arena, it is not implausible that numerous tissue samples may 
be leaving SA and Africa for genetic research purposes.[29] The 
Majengo and San cases outline the positive outcomes of benefit 
sharing arrangements with research participants. The University of 
the Witwatersrand’s MTA template highlights that benefit sharing 
should be discussed between parties before tissues are transferred 
in order to foster equitable benefit sharing arrangements. 
Furthermore, international ethical guidelines relevant to human 
materials shape the importance of benefit sharing as a progressive 
mechanism for parties to adopt as part of the research process. 
According to Slabbert:[30] ‘The challenge for South Africa is to find 
a benefit­sharing model that tempers (not diminish) commercial 
interests; that redresses economic imbalance; and that gives 
research participants a more fair and active role in influencing the 
sharing of benefits…’[30] The Biodiversity Act provides an excellent 
starting point to develop a model similar in nature for human 
biological material. This will enhance confidence and trust in 
genetic research, which will in turn ensure a sustainable research 
environment for both research participants and institutions.
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